z-logo
open-access-imgOpen Access
Oxidative Stress-Responsive Transcription Factor ATF3 Potentially Mediates Diabetic Angiopathy
Author(s) -
Aki Okamoto,
Yasuhiko Iwamoto,
Yoshiro Maru
Publication year - 2006
Publication title -
molecular and cellular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.14
H-Index - 327
eISSN - 1067-8824
pISSN - 0270-7306
DOI - 10.1128/mcb.26.3.1087-1097.2006
Subject(s) - activating transcription factor , biology , vascular endothelial growth factor , angiogenesis , microbiology and biotechnology , atf3 , transcription factor , vascular endothelial growth factor a , oxidative stress , gene expression , cancer research , endocrinology , promoter , gene , genetics , vegf receptors
Previous results of our cDNA microarray analysis to look for genes whose expression level correlates well with in vitro tubulogenesis by NP31 endothelial cells revealed the transcription factor ATF3 known to be responsive to stress such as reactive oxygen species (ROS). Anti-ATF3 small interfering RNA gave an inhibitory influence on tube formation by NP31 cells expressing an activated form of the vascular endothelial growth factor receptor 1 (VEGFR-1) kinase. When expression of ATF3 was regulated under the control of tetracycline system in NP31 cells, they acquired the tubulogenic ability upon ATF3 induction. While ATF3 failed to induce expressions of VEGF and VEGFR, it regulated those of CDK2, CDK4, p8, plasminogen activator inhibitor 1, integrin α1, subunit and matrix metalloprotease MMP13. In H2 O2 -stimulated NP31 cells as well as endothelial cells of glomerulus and aorta of Otsuka-Long-Evans-Tokushima-Fatty diabetic model rats, concomitantly enhanced expressions of ATF3, PAI-1, and p8 were observed. Given the proposed hypothesis of the close linkage between diabetic angiopathy and ROS, those data suggest that ROS-associated diabetic complication may involve ATF3-mediated pathological angiogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here